Okuda Y - Search Results

1

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.

Takahashi S, Karayama M, Takahashi M, Watanabe J, Minami H, Yamamoto N, Kinoshita I, Lin CC, Im YH, Achiwa I, Kamiyama E, Okuda Y, Lee C, Bang YJ. Takahashi S, et al. Among authors: okuda y. Clin Cancer Res. 2021 Nov 1;27(21):5771-5780. doi: 10.1158/1078-0432.CCR-21-1560. Epub 2021 Aug 23. Clin Cancer Res. 2021. PMID: 34426442 Free PMC article. Clinical Trial.

2

Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.

Ito S, Itoh H, Rakugi H, Okuda Y, Iijima S. Ito S, et al. Among authors: okuda y. Hypertens Res. 2021 May;44(5):489-497. doi: 10.1038/s41440-020-00585-y. Epub 2020 Dec 16. Hypertens Res. 2021. PMID: 33323991 Free PMC article.

3

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T; DESTINY-CRC01 investigators. Siena S, et al. Among authors: okuda y. Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4. Lancet Oncol. 2021. PMID: 33961795 Clinical Trial.

4

Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.

Takahashi S, Bando H, Kinoshita I, Modi S, Tsurutani J, Bang YJ, Sato Y, Nakatani S, Lee C, Sugihara M, Okuda Y, Iwata H. Takahashi S, et al. Among authors: okuda y. Jpn J Clin Oncol. 2024 Apr 6;54(4):434-443. doi: 10.1093/jjco/hyad181. Jpn J Clin Oncol. 2024. PMID: 38231777 Free PMC article.

5

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.

Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Ito S, et al. Among authors: okuda y. J Hum Hypertens. 2019 Jul;33(7):542-551. doi: 10.1038/s41371-019-0207-x. Epub 2019 May 21. J Hum Hypertens. 2019. PMID: 31113987 Free PMC article. Clinical Trial.

6

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Ito S, et al. Among authors: okuda y. Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1161-1172. doi: 10.2215/CJN.14751218. Epub 2019 Jun 27. Clin J Am Soc Nephrol. 2019. PMID: 31248950 Free PMC article. Clinical Trial.

7

Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.

Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Rakugi H, et al. Among authors: okuda y. Hypertens Res. 2019 Dec;42(12):1932-1941. doi: 10.1038/s41440-019-0314-7. Epub 2019 Sep 25. Hypertens Res. 2019. PMID: 31554937 Free PMC article. Clinical Trial.

8

Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.

Satoh F, Ito S, Itoh H, Rakugi H, Shibata H, Ichihara A, Omura M, Takahashi K, Okuda Y, Iijima S. Satoh F, et al. Among authors: okuda y. Hypertens Res. 2021 Apr;44(4):464-472. doi: 10.1038/s41440-020-00570-5. Epub 2020 Nov 16. Hypertens Res. 2021. PMID: 33199881 Free PMC article.

9

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.

Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, Sawanobori T. Ito S, et al. Among authors: okuda y. Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1715-1727. doi: 10.2215/CJN.06870520. Epub 2020 Nov 25. Clin J Am Soc Nephrol. 2020. PMID: 33239409 Free PMC article. Clinical Trial.

10

Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.

Toyama K, Furuie H, Kuroda K, Ishizuka T, Okuda Y, Shimizu T, Kato M, Igawa Y, Nishikawa Y, Ishizuka H. Toyama K, et al. Among authors: okuda y. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):685-694. doi: 10.1007/s13318-021-00701-4. Epub 2021 Aug 12. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34383278 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,185 results

Search Page

Filters